慢性乙型肝炎患者抗病毒治疗疗效及其影响因素研究.docVIP

慢性乙型肝炎患者抗病毒治疗疗效及其影响因素研究 　　【摘要】 目的：探讨慢性乙型肝炎患者抗病毒治疗的效果及其影响因素。方法：选取2014年1月-2015年1月在本院就诊的慢性乙型肝炎患者300例。随机数字表法分成治疗组和对照组各150例，治疗组患者采用抗病毒药物进行治疗，对照组患者采用免疫调节类药物进行治疗，比较不同治疗方案的治疗效果。结果：两组患者在治疗第4周以及治疗结束后，ALT恢复例数差异不具有统计学意义；治疗第12周以及第24周时，治疗组ALT转阴情况优于对照组，比较差异有统计学意义（P0.05），其中第24周时差异具有显著统计学意义（P0.01）。HBeAg恢复情况与HBV-DNA检测结果比较显示，两组患者在治疗第4、12周，HBeAg恢复例数差异不具有统计学意义；治疗第24周以及治疗结束时，HBeAg转阴情况优于对照组，比较差异具有显著统计学意义（P0.01）。结论：抗病毒药物临床起效较快，药物用作较明显，同时对于HBV的抑制效果较干扰素治疗更为明显和有效。也存在一些有待解决的问题，值得不断的探索、研究。 　　【关键词】 慢性乙型肝炎； 抗病毒治疗； 疗效； 影响因素 　　Patients with Chronic Hepatitis B Antiviral Treatment Curative Effect and Influencing Factors of Research/DENG Li-hong， LIU Tian-huang， HE Zong-yun.//Medical Innovation of China，2015，12（22）：025-027 　　【Abstract】 Objective： To study the treatment effect of patients with chronic hepatitis b antiviral and extremely influence factors. Method： To select between January 2014 and January 2014 in our hospital 300 chronic hepatitis b patients， and randomly divided them into treatment group and control group， each contained 150 cases， the treatment group was treated by antiviral drug treatment， the control group was treated by immunomodulatory drugs， to compare different therapeutic effect between the two groups. Result： After 4 weeks and at the end of treatment， ALT had no significant difference in the patient number. Treatment for 12 weeks and 24 weeks， ALT overcast conditions of the treatment group was better than that of the control group， there was significantly different at 24 weeks （P0.01）. HBeAg recovery compared with HBV-DNA test results showed that in the treatment of 4 weeks and 12 weeks， HBeAg recovery had no significant difference. 24 weeks， and at the end of treatment， HBeAg overcast conditions of the treatment group was better than that of the control group， with significant difference （P0.01）. Conclusion： Antiviral drugs clinical work faster， as is obvious， at the same time for HBV inhibition effect is more obvious and effective interferon treatment. There are still